ENTRESTO® (Sacubitril / Valsartan)

Heart Failure Novartis Medicines

ENTRESTO® is a novel angiotensin receptor/neprilysin inhibitor (ARNI) indicated for use in adult patients for the treatment of chronic heart failure (NYHA Class II-IV) with reduced ejection fraction.¹
ENTRESTO® combines action of sacubitril, a prodrug whose active metabolite inhibits neprilysin, and valsartan, an angiotensin II type-1 (AT1) receptor antagonist.¹
In the PARADIGM clinical trial, ENTRESTO® has demonstrated statistically significant superiority to enalapril, reducing the risk of cardiovascular death or heart failure hospitalizations by 20% (p<0.0001)¹.
ENTRESTO® is indicated to reduce the risk of cardiovascular death and for heart failure in adult patients with chronic heart failure
Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below Normal. LVEF is a variable measure, so use clinical judgment in deciding whom to treat.